Non-Hodgkin Lymphoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Non-Hodgkin Lymphoma Market is Segmented By Disease Type (B-cell Lymphomas, T-cell Lymphoma), By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, PD1 Inhibitors, Immunomodulatory Drugs, Chemotherapy Agents, CAR T-Cell Therapy), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Non-Hodgkin Lymphoma Market Size

The Global Non-Hodgkin Lymphoma Market reached USD 7.3 billion in 2023 and is projected to witness lucrative growth by reaching up to USD 13.5 billion by 2031. The global non-Hodgkin lymphoma market is expected to exhibit a CAGR of 8.2% during the forecast period 2024-2031. Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the body's immune system.

It involves the abnormal growth of lymphocytes, a type of white blood cell that helps fight infections. NHL encompasses a diverse group of lymphomas with various subtypes, each with its own characteristics and treatment approaches.

Treatment for NHL depends on the subtype, stage of the disease, and individual patient factors. The main treatment modalities include chemotherapy, radiation therapy, immunotherapy, targeted therapy, and stem cell transplantation. The choice of treatment aims to achieve remission, alleviate symptoms, and prolong survival. Treatment may involve a combination of these modalities and is often tailored to each patient's specific needs.

Furthermore, the increasing incidence and prevalence of non-Hodgkin lymphoma, evolving treatment landscape, and the growing adoption of immunotherapies are the factors expected to drive over the forecast period.

Non-Hodgkin Lymphoma Market Scope

To Know More Insights - Download Sample

Non-Hodgkin Lymphoma Market Dynamics

The Growing Regulatory Approvals for Non-Hodgkin Lymphoma is Expected to Drive Global Non-Hodgkin Lymphoma Market

On March 23, 2023, the National Medical Products Administration (NMPA) in China conditionally approved AstraZeneca's Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This marks the first approved indication for Calquence in China.

The conditional approval was granted based on positive results from two clinical trials. The first trial, ACE-LY-004, was a global Phase II trial that included adults with relapsed or refractory MCL. The second trial was a Phase I/II trial conducted specifically in Chinese patients with relapsed or refractory MCL and other B-cell malignancies. The NMPA will continue to assess the ongoing randomized controlled confirmatory trials for further approval.

The Increasing Clinical Trials for Non-Hodgkin Lymphoma Drugs is Expected to Drive Global Non-Hodgkin Lymphoma Market 

According to ClinicalTrials.gov, in 2022, the Abramson Cancer Center at Penn Medicine conducted a Phase II clinical trial to evaluate the efficacy of RADVAX in the treatment of relapsed/refractory Non-Hodgkin Lymphoma (NHL). 

The study involved the combination of pembrolizumab (an immunotherapy drug) with low-dose radiotherapy. The estimated completion date for this study is December 2023. The trial aims to assess the effectiveness and safety of this treatment approach in patients with NHL who have experienced relapse or have not responded to previous therapies.

Lack of Specific Targeted Therapies for Treating Non-Hodgkin Lymphoma is Expected to Hamper Global Non-Hodgkin Lymphoma Market

Despite the success of targeted therapies in treating select NHL subtypes, there remains a requirement for more precise and potent targeted treatments that can address a wider range of NHL subtypes. Limited treatment options for certain NHL subtypes impede market growth within the field.

For instance, Peripheral T-cell Lymphoma (PTCL) is a heterogeneous group of NHL subtypes with limited treatment options. Currently, there are no targeted therapies specifically approved for PTCL. Chemotherapy regimens are often used, but the prognosis for PTCL patients remains relatively poor. Developing targeted therapies that can address the unique characteristics of PTCL subtypes is an area of unmet need. Hence, owing to the above factors, the market is expected to hamper over the forecast period.

Non-Hodgkin Lymphoma Market Segment Analysis

The global non-Hodgkin lymphoma market is segmented based on disease type, drug class, route of administration, distribution channel, and region.

Owing to the Increasing Prevalence of B-cell Lymphomas, Rising Clinical Trials, the Disease Type Segment Accounted for Approximately 52.6% of the Non-Hodgkin Lymphoma Market Share 

B-cell lymphomas are a group of lymphoid malignancies that arise from abnormal B-cells, which are a type of white blood cell involved in the immune response. These lymphomas are characterized by the clonal proliferation of B-cells that have undergone genetic or molecular alterations.

There are numerous subtypes of B-cell lymphomas, each with distinct clinical, pathological, and molecular features. Some common subtypes include Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Burkitt Lymphoma among others. Furthermore, the increasing prevalence of Diffuse Large B-cell Lymphoma (DLBCL), the rising clinical trials, and rising investment in the drugs are the factors expected to drive the market over the forecast period.

For instance, according to the article from the National Center for Biotechnology Information published on April 24, 2023, the annual incidence of non-Hodgkin lymphoma (NHL) in the United States is estimated to be around 7 cases per 100,000 individuals. Among all NHL cases worldwide, diffuse large B-cell lymphoma (DLBCL) accounts for approximately 25%. DLBCL is the most prevalent subtype of NHL, followed by follicular lymphoma (FL).

Source: DataM Intelligence Analysis (2023)

Non-Hodgkin Lymphoma Market Geographical Share

North America Accounted for Approximately 41.9% of the Market Share in 2022, Owing to the Increasing Research and Development Activities and Well-Established Healthcare Infrastructure  

The North American region is anticipated to experience growth in the field of non-Hodgkin lymphoma treatments due to factors such as rising research and development efforts, a robust healthcare infrastructure, and supportive reimbursement systems. These factors contribute to increased accessibility for patients to access advanced therapies, facilitating the adoption of cutting-edge treatments. This trend is expected to drive the North American region's progress in non-Hodgkin lymphoma treatment throughout the forecast period.

For instance, according to an article from the National Cancer Institute, the primary focus of current research on non-Hodgkin lymphoma treatment is centered around targeted therapy and immunotherapy. The emphasis is on developing treatments that specifically target the underlying molecular and genetic changes associated with different types of lymphoma. Researchers are actively working to identify specific gene alterations that could serve as potential targets for the development of new drugs in the field of lymphoma treatment.

Furthermore, the presence of renowned research institutions and academic centers fosters collaboration between scientists, clinicians, and industry experts, facilitating knowledge exchange and accelerating the pace of innovation in non-Hodgkin lymphoma treatments. Hence, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Non-Hodgkin Lymphoma Market Companies

The major global players in the market include AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd. among others.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of diseases such as non-Hodgkin lymphoma (NHL). The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, may be damaged or inaccessible, making it challenging for patients with NHL to receive proper diagnosis, treatment, and follow-up care.

The conflict resulted in limited availability of medical resources, including diagnostic equipment, medications, and specialized healthcare professionals. This scarcity may lead to delays in diagnosis, inadequate treatment options, and suboptimal disease management for NHL patients. The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement can disrupt patients' continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their NHL treatment.

Furthermore, the conflict and its aftermath hinder data collection and research efforts related to NHL in the affected regions. This can impact the availability of up-to-date epidemiological data, hinder clinical trials, and limit the understanding of NHL patterns and treatment outcomes in the conflict-affected areas. Therefore, considering the aforementioned factors, the Non-Hodgkin Lymphoma market has been moderately affected by the conflict between Russia and Ukraine.

By Disease Type

• B-cell Lymphomas
• T-cell Lymphoma

By Drug Class

• Monoclonal Antibodies
• Antibody-Drug Conjugates
• BTK/BCL-2 Kinase Inhibitors
• PI3 Kinase Inhibitors
• Protease Inhibitors
• PD1 Inhibitors
• Immunomodulatory Drugs
• Chemotherapy Agents
• CAR T-Cell Therapy
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• Genentech, a member of the Roche Group, announced on December 22, 2022, that the U.S. Food and Drug Administration (FDA) granted approval for Lunsumio (mosunetuzumab-axgb) in the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone two or more lines of systemic therapy. The approval is granted under an accelerated approval pathway based on response rate, and further confirmation of clinical benefit will be required in a confirmatory trial for continued approval. Lunsumio is a novel fixed-duration cancer immunotherapy that belongs to the CD20xCD3 T-cell-engaging bispecific antibody class. It is readily available off-the-shelf, allowing patients to commence treatment without delay.
• On January. 27, 2023, Loxo Lilly, the oncology unit of Eli Lilly and Company, announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. 

Jaypirca was approved under the FDA's Accelerated Approval pathway based on the response rate from the open-label, single-arm, international, Phase 1/2 study, called the BRUIN trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

• Genentech, a member of the Roche Group, announced on January 5, 2023, that the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody. The FDA has granted Priority Review to glofitamab for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. LBCL is a particularly aggressive form of non-Hodgkin's lymphoma (NHL) and is prevalent among adults in the U.S.

Why Purchase the Report?

• To visualize the global non-Hodgkin lymphoma market segmentation based on the disease type, drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of non-Hodgkin lymphoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global non-Hodgkin lymphoma market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies